Synonyms: BAY 94-9343
Anetumab ravtansine (BAY 94-9343) is an antibody-drug conjugate (ADC) composed of a human anti-mesothelin antibody and a cytotoxic maytansinoid tubulin inhibitor DM4. Anetumab ravtansine has the potential to treat advanced solid tumors.
CAS No. 1375258-01-7
Shimon Sakaguchi
Nature Communications 2025,16, Article number:1325
David Baker
Dev Cell 2023, 58(20):2163-2180.e9.
David Julius
Cell 2017, 185-198.e16
Michael Houghton
Cell Chem Biol, 2020, 27(7):780-792.e5
Charles M. Rice
Cell 2018, 172(3):423-438.e25
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Description |
Anetumab ravtansine (BAY 94-9343) is an antibody-drug conjugate (ADC) composed of a human anti-mesothelin antibody and a cytotoxic maytansinoid tubulin inhibitor DM4. Anetumab ravtansine has the potential to treat advanced solid tumors.
|
References |
|---|
| CAS No. | 1375258-01-7 |
|---|---|
| ADC antiody | Anetumab |
| ADC cytotoxin | DM4 |
| Formulation | 100 mM Pro-Ac, 20 mM Arg-Ac, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT03816358 | ACTIVE_NOT_RECRUITING | Drug: Gemcitabine Hydrochloride | Pancreatic Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8 | National Cancer Institute (NCI) | 2019-12-09 | PHASE1 |
| NCT03587311 | ACTIVE_NOT_RECRUITING | Drug: Paclitaxel | Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma | National Cancer Institute (NCI) | 2018-10-12 | PHASE2 |
| NCT03126630 | ACTIVE_NOT_RECRUITING | Pleural Malignant Mesothelioma | National Cancer Institute (NCI) | 2018-10-04 | PHASE1; PHASE2 | |
| NCT03926143 | TERMINATED | Drug: BAY94-9343 (Anetumab ravtansine) | Solid Tumors | Bayer | 2019-06-03 | PHASE2 |
| NCT03102320 | COMPLETED | Drug: Cisplatin|Drug: Gemcitabine|Drug: Anetumab ravtansine | Neoplasms | Bayer | 2017-05-26 | PHASE1 |
| NCT03455556 | TERMINATED | Mesothelin Positive; Stage III Non-Small Cell Lung Cancer AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7; Stage IIIB Non-Small Cell Lung Cancer AJCC v7; Stage IV Non-Small Cell Lung Cancer AJCC v7 | Mayo Clinic | 2018-08-10 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-07-21)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.